Category: Products

Felixvet Introduces Firocoxib Tablets for Horses for the Control of Osteoarthritis Pain and Inflammation

Posted on by developer@wearewoodruff.com

Kansas City, Mo. — July 21, 2026 — Felixvet Inc. today announced the commercial availability of Firocoxib Tablets for Horses, an FDA-approved non-steroidal anti-inflammatory drug (NSAID) indicated for the control of pain and inflammation associated with osteoarthritis in horses. Approved by the U.S. Food and Drug Administration on February 23, 2026, under ANADA 200-841, the product expands Felixvet’s growing animal health portfolio and provides veterinarians and horse owners with an important treatment option for managing equine osteoarthritis.

Product Details

Two white plastic bottles of Firocoxib Tablets for Horses shown in 60-count and 180-count size bottles.
Felixvet Firocoxib Tablets for Horses are indicated for the control of pain and inflammation associated with osteoarthritis in horses.

“We’re excited to expand Felixvet’s portfolio into the equine market with the introduction of Firocoxib Tablets for Horses,” said Lauren Landolph, Vice President, Commercial Strategy & Distribution Channels, Felixvet. “Osteoarthritis is one of the most common causes of pain and reduced mobility in horses, and we’re proud to provide veterinarians and horse owners with an FDA-approved treatment option that helps support equine comfort and performance.”

Osteoarthritis is one of the most common causes of chronic pain and reduced mobility in horses. Firocoxib Tablets for Horses are administered once daily for up to 14 days for the control of pain and inflammation associated with osteoarthritis in horses.

The product is therapeutically equivalent to the pioneer drug and provides the same safety and efficacy profile. Available as a 57 mg chewable tablet, Firocoxib Tablets for Horses feature a palatable beef flavor and a scored tablet design to support easy administration and accurate dosing. The product is available in 60-count and 180-count bottle presentations.

“At Felixvet, we’re committed to bringing high-quality veterinary medicines to market that address meaningful needs across animal health,” added Lauren Landolph. “The addition of Firocoxib Tablets for Horses reflects our continued investment in providing trusted treatment options for veterinarians, horse owners, and the animals in their care.”

Felixvet continues to expand its portfolio of FDA-approved animal health products, supporting veterinarians and animal owners with high-quality, accessible treatment options across companion animal and equine therapeutic categories.

For additional information, please contact info@felixvet.com

About Felixvet

Founded in 2015 by Dr. Shumeet Banerji, Jon Symonds and Neeraj Agrawal, Felix develops and commercializes high-quality, bioequivalent pharmaceutical products for companion animals. The company is focused on expanding access to FDA-approved veterinary medicines through a growing portfolio of trusted treatment options for veterinarians and pet owners.

Media Contact

Paula Flavin
Project Marketing Manager, US Operations
D: 816-912-2000
E: info@felixvet.com

Felixvet Introduces Firocoxib Chewable Tablets for Dogs for the Control of Osteoarthritis and Postoperative Pain

Posted on by developer@wearewoodruff.com

Kansas City, Mo. — July 21, 2026 — Felixvet Inc. today announced the commercial availability of Firocoxib Chewable Tablets for Dogs, an FDA-approved non-steroidal anti-inflammatory drug (NSAID) indicated for the control of pain and inflammation associated with osteoarthritis and for the control of postoperative pain and inflammation associated with soft tissue and orthopedic surgery in dogs. Approved by the U.S. Food and Drug Administration on August 3, 2023, under ANADA 200-755, the product provides veterinarians with a trusted treatment option for both chronic and postoperative pain management.

Product Details

Four white plastic prescription bottles of Firocoxib Chewable Tablets for dogs in 227 mg and 57 mg strengths.
Felixvet Firocoxib Chewable Tablets are indicated for the control of pain and inflammation associated with osteoarthritis and postoperative pain and inflammation associated with soft tissue and orthopedic surgery in dogs.

“Pain management is a critical component of both long-term care and postoperative recovery in dogs,” said Lauren Landolph, Vice President, Commercial Strategy & Distribution Channels, Felixvet. “We’re excited to bring Firocoxib Chewable Tablets to the veterinary market and provide veterinarians with an FDA-approved treatment option that supports canine comfort, mobility, and recovery.”

Firocoxib Chewable Tablets are indicated for the control of pain and inflammation associated with osteoarthritis and for the control of postoperative pain and inflammation associated with soft tissue and orthopedic surgery in dogs.

The product is available in two strengths:

  • 57 mg chewable tablets 
  • 227 mg chewable tablets 

Designed to support convenient administration and dosing flexibility, the tablets feature an appealing artificial meat flavor and are scored for easy and accurate dosing. The product is available in both 60-count and 180-count bottle presentations.

“Veterinarians rely on effective pain management therapies every day, whether supporting aging dogs with osteoarthritis or helping patients recover following surgery,” added Lauren Landolph. “The addition of Firocoxib Chewable Tablets reflects Felixvet’s continued commitment to providing high-quality treatment options that support better outcomes for companion animals.”

Felixvet continues to expand its portfolio of FDA-approved companion animal pharmaceuticals, supporting veterinarians and pet owners with high-quality treatment options across a broad range of therapeutic categories.

For additional information, please contact info@felixvet.com.

About Felixvet

Founded in 2015 by Dr. Shumeet Banerji, Jon Symonds and Neeraj Agrawal, Felix develops and commercializes high-quality, bioequivalent pharmaceutical products for companion animals. The company is focused on expanding access to FDA-approved veterinary medicines through a growing portfolio of trusted treatment options for veterinarians and pet owners.

Media Contact

Paula Flavin
Project Marketing Manager, US Operations
D: 816-912-2000
E: info@felixvet.com

Felixvet Introduces Praziquantel Tablets 23 mg for the Removal of Tapeworm Infections in Cats

Posted on by developer@wearewoodruff.com

Kansas City, Mo. — July 16, 2026 — Felixvet Inc. today announced the commercial availability of Praziquantel Tablets 23 mg, an FDA-approved feline cestocide indicated for the removal of Dipylidium caninum and Taenia taeniaeformis tapeworm infections in cats. Approved by the U.S. Food and Drug Administration on December 22, 2025, under ANADA 200-834, the product expands Felixvet’s growing portfolio of companion animal pharmaceuticals and provides veterinarians with an important treatment option for managing common feline tapeworm infections.

Product Details

Three white plastic bottles of Praziquantel Tablets for cats, shown in decreasing sizes containing 150, 50 and 3 chewable tablets.
Felixvet Praziquantel Tablets 23 mg are indicated for the removal of Dipylidium caninum and Taenia taeniaeformis tapeworm infections in cats.

“We’re excited to bring Praziquantel Tablets 23 mg to the veterinary market and expand access to an important treatment option for feline patients,” said Lauren Landolph, Vice President, Commercial Strategy & Distribution Channels, Felixvet. “Tapeworm infections remain a common concern in cats, and this approval provides veterinarians and pet owners with an FDA-approved chewable tablet designed to support effective treatment and ease of administration.”

Praziquantel Tablets 23 mg are indicated for the removal of Dipylidium caninum and Taenia taeniaeformis, two of the most commonly encountered tapeworm species affecting cats. The product is sized for easy oral administration and may be administered directly or crumbled and mixed with food. 

The product is therapeutically equivalent to the pioneer drug and provides the same safety and efficacy profile. Praziquantel Tablets are available in a single 23 mg strength and feature a palatable beef flavor. Each chewable tablet is scored to support easy and accurate dosing. 

Praziquantel Tablets 23 mg are available in:

  • 3-count chewable tablet bottles 
  • 50-count chewable tablet bottles 
  • 150-count chewable tablet bottles 

“At Felixvet, we’re committed to providing veterinarians with trusted treatment options across a broad range of therapeutic categories,” added Lauren Landolph. “The addition of Praziquantel Tablets 23 mg reflects our continued focus on expanding access to high-quality products that support the health and well-being of companion animals.”

Felixvet continues to expand its portfolio of FDA-approved companion animal pharmaceuticals, supporting veterinarians and pet owners with high-quality, bioequivalent treatment options across companion animal medicine.

For additional information, please contact info@felixvet.com

About Felixvet

Founded in 2015 by Dr. Shumeet Banerji, Jon Symonds and Neeraj Agrawal, Felix develops and commercializes high-quality, bioequivalent pharmaceutical products for companion animals. The company is focused on expanding access to FDA-approved veterinary medicines through a growing portfolio of trusted treatment options for veterinarians and pet owners.

Media Contact

Paula Flavin
Project Marketing Manager, US Operations
D: 816-912-2000
E: info@felixvet.com

Felixvet Introduces First FDA-Approved Generic Methimazole Tablets for the Treatment of Hyperthyroidism in Cats

Posted on by developer@wearewoodruff.com

Kansas City, Mo. — July 14, 2026 — Felixvet Inc. today announced the commercial availability of Methimazole Coated Tablets, the first FDA-approved generic version of methimazole tablets for the treatment of hyperthyroidism in cats and a therapeutically equivalent alternative to Felimazole®. Approved by the U.S. Food and Drug Administration (FDA) on July 22, 2025, Methimazole Coated Tablets provide veterinarians with a trusted new option for the management of one of the most commonly diagnosed endocrine disorders in feline patients.

Product Details

Two white plastic prescription bottles of Methimazole Coated Tablets for cats, showing a 5 mg strength bottle next to a 2.5 mg strength bottle.
Felixvet Methimazole Coated Tablets are available in 2.5 mg and 5 mg strengths for oral use in cats only. 

“We’re incredibly excited to bring the first FDA-approved generic methimazole tablets to the veterinary market,” said Lauren Landolph, Vice President, Commercial Strategy & Distribution Channels at Felixvet. “Methimazole has been a cornerstone therapy for the management of feline hyperthyroidism for many years, and this approval represents an important opportunity to expand access to a trusted treatment option for veterinarians, pet owners, and the cats they care for.”

Hyperthyroidism is a common endocrine disorder in cats caused by excessive production of thyroid hormones. Clinical signs may include weight loss, increased appetite, increased thirst and urination, vomiting, and hyperactivity. Methimazole Coated Tablets help manage the disease by inhibiting the synthesis of thyroid hormones. 

The FDA approved Methimazole Coated Tablets (ANADA 200-814) after determining the product is bioequivalent to the pioneer drug, Felimazole® (NADA 141-292). The approval followed a comprehensive review of the product’s safety, effectiveness, and manufacturing quality.

Felixvet’s Methimazole Coated Tablets are available in:

  • 2.5 mg coated tablets – 100-count bottles 
  • 5 mg coated tablets – 100-count bottles 

The tablets are film-coated and intended for oral administration in cats. Methimazole Coated Tablets are therapeutically equivalent to the pioneer product and provide veterinarians with an FDA-approved treatment option for the long-term management of feline hyperthyroidism. 

Felixvet continues to expand its portfolio of FDA-approved companion animal pharmaceuticals, supporting veterinarians and distribution partners with high-quality, bioequivalent treatment options across key therapeutic categories.

For additional information, please contact info@felixvet.com

About Felixvet

Founded in 2015 by Dr. Shumeet Banerji, Jon Symonds and Neeraj Agrawal, Felix develops and commercializes high-quality, bioequivalent pharmaceutical products for companion animals. The company is focused on expanding access to FDA-approved veterinary medicines through a growing portfolio of trusted treatment options for veterinarians and pet owners.

Media Contact

Paula Flavin
Project Marketing Manager, US Operations
D: 816-912-2000
E: info@felixvet.com

Felixvet Introduces Clomipramine Hydrochloride Tablets for the Treatment of Separation Anxiety in Dogs

Posted on by developer@wearewoodruff.com

Kansas City, Mo. — July 9, 2026 — Felixvet Inc. today announced the commercial availability of Clomipramine Hydrochloride Tablets, an FDA-approved treatment indicated for separation anxiety in dogs greater than six months of age when used as part of a comprehensive behavioral management program. Approved by the U.S. Food and Drug Administration (FDA) on October 21, 2025, Clomipramine Hydrochloride Tablets are therapeutically equivalent to the pioneer product and provide veterinarians with a trusted treatment option for managing one of the most common behavioral conditions seen in companion animal practice.

Product Details

Four white bottles of Clomipramine Hydrochloride Tablets for dogs, lined up to show different dosage strengths of 5 mg, 20 mg, 40 mg and 80 mg.
Felixvet Clomipramine Hydrochloride Tablets are available in 5 mg, 20 mg, 40 mg and 80 mg strengths for oral administration in dogs.

“Behavioral health is an important part of overall animal health, and separation anxiety remains one of the most common challenges veterinarians help pet owners address,” said Lauren Landolph, Vice President, Commercial Strategy & Distribution Channels, Felixvet. “We’re excited to bring Clomipramine Hydrochloride Tablets to market and provide veterinarians with another FDA-approved treatment option that can help improve outcomes for both dogs and their families.”

Clomipramine Hydrochloride Tablets are indicated for use as part of a comprehensive behavioral management program to treat separation anxiety in dogs greater than six months of age and are intended to be used in conjunction with behavior modification techniques.

Felixvet’s Clomipramine Hydrochloride Tablets are available in:

  • 5 mg tablets 
  • 20 mg tablets 
  • 40 mg tablets 
  • 80 mg tablets 

All strengths are supplied in 30-count bottles and are formulated for oral administration in dogs. The product is therapeutically equivalent to the pioneer drug and offers the same safety and efficacy profile.

Felixvet continues to expand its portfolio of FDA-approved companion animal pharmaceuticals, supporting veterinarians and distribution partners with high-quality, bioequivalent treatment options across key therapeutic categories.

For additional information, please contact info@felixvet.com

About Felixvet

Founded in 2015 by Dr. Shumeet Banerji, Jon Symonds and Neeraj Agrawal, Felix develops and commercializes high-quality, bioequivalent pharmaceutical products for companion animals. The company is focused on expanding access to FDA-approved veterinary medicines through a growing portfolio of trusted treatment options for veterinarians and pet owners.

Media Contact

Paula Flavin
Project Marketing Manager, US Operations
D: 816-912-2000
E: info@felixvet.com

Felixvet Expands Companion Animal Portfolio with Clindamycin Hydrochloride Tablets

Posted on by developer@wearewoodruff.com

Kansas City, Mo. — July 7, 2026 — Felixvet Inc. today announced the addition of Clindamycin Hydrochloride Tablets to its growing product portfolio. The product received approval from the U.S. Food and Drug Administration (FDA) on June 27, 2025 and is indicated for the treatment of skin infections, wounds and abscesses, dental infections, and osteomyelitis in dogs caused by susceptible bacterial organisms.

“Veterinarians manage bacterial infections every day, and they need treatment options they can trust and prescribe with confidence,” said Lauren Landolph, Vice President, Commercial Strategy & Distribution Channels at Felixvet. “The addition of Clindamycin Hydrochloride Tablets expands access to an important antimicrobial while supporting the practical needs of veterinary teams and pet owners.”

Product Details

Three white plastic bottles of Clindamycin Hydrochloride Tablets for dogs, lined up side-by-side to showcase three different strengths: 150 mg, 75 mg and 25 mg.
Available in 25 mg, 75 mg and 150 mg strengths.

Clindamycin Hydrochloride Tablets provide veterinarians with an FDA-approved, bioequivalent option for the treatment of select bacterial infections in dogs, including skin infections, deep wounds and abscesses, dental infections, and osteomyelitis.

Available configurations include:

  • 25 mg tablets – 400-count bottles 
  • 75 mg tablets – 200-count bottles 
  • 150 mg tablets – 100-count bottles 

Each tablet is scored to support accurate dosing and administration and is therapeutically equivalent to the pioneer drug.

“We’re focused on building a portfolio around the products veterinarians use every day,” added Lauren Landolph. “Clindamycin Hydrochloride Tablets are an important addition to that strategy and reflect our commitment to delivering trusted veterinary treatment options.”

About Felixvet

Founded in 2015 by Dr. Shumeet Banerji, Jon Symonds and Neeraj Agrawal, Felix is focused on developing and commercializing high-quality, bioequivalent generic pharmaceutical products for companion animals. The company’s initial focus is to market and distribute these products throughout North America following approval by the U.S. Food and Drug Administration and Health Canada.

Focused exclusively on animal health, Felixvet has established research, development, manufacturing, and commercial capabilities designed to support the evolving needs of veterinary medicine. The company continues to expand its portfolio of FDA-approved pharmaceuticals, providing veterinarians with trusted treatment options across the therapeutic categories they prescribe every day. 

Felixvet aims to be the first truly global generic companion animal pharmaceutical company serving the world’s leading veterinary markets while making high-quality, bioequivalent medicines more accessible to veterinarians, pet owners, and the animals they care for.

Media Contact

Paula Flavin
Project Marketing Manager, US Operations
D: 816-912-2000
E: info@felixvet.com

Felixvet Introduces Dexmedetomidine Hydrochloride Injectable Solution for Sedation, Analgesia, and Preanesthetic Use in Dogs and Cats

Posted on by developer@wearewoodruff.com

Kansas City, Mo. — July 2, 2026 — Felixvet Inc. today announced the commercial availability of Dexmedetomidine Hydrochloride Sterile Injectable Solution 0.5 mg/mL, an FDA-approved sedative, analgesic, and preanesthetic indicated for use in dogs and cats. Approved by the U.S. Food and Drug Administration (FDA) on September 19, 2025, Dexmedetomidine Hydrochloride is indicated to facilitate clinical examinations, clinical procedures, minor surgical procedures, and minor dental procedures, and may also be used as a preanesthetic to general anesthesia in dogs and cats.

Product Details

A 10 mL glass vial and matching blue-and-white display box for Dexmedetomidine Hydrochloride sterile injectable solution.
Felixvet Dexmedetomidine Hydrochloride is available as a sterile injectable solution containing 0.5 mg/mL (5 mg/10 mL).

“From routine examinations to minor procedures and anesthesia protocols, veterinarians rely on products like Dexmedetomidine every day,” said Lauren Landolph, Vice President, Commercial Strategy & Distribution Channels, Felixvet. “We’re excited to bring this important product to market and provide veterinary professionals with another trusted, FDA-approved option for both canine and feline patients.”

Dexmedetomidine Hydrochloride is indicated for use as a sedative and analgesic in dogs and cats to facilitate clinical examinations, clinical procedures, minor surgical procedures, and minor dental procedures. The product is also indicated for use as a preanesthetic to general anesthesia in both species.

Dexmedetomidine Hydrochloride is available as a 0.5 mg/mL sterile injectable solution supplied in a 10 mL multidose vial.

The product is approved for intramuscular and intravenous use in dogs and for intramuscular use in cats. Dexmedetomidine Hydrochloride is therapeutically equivalent to the pioneer product and provides veterinarians with an FDA-approved option for sedation, analgesia, and preanesthetic use in companion animal patients.

Felixvet continues to expand its portfolio of FDA-approved companion animal pharmaceuticals, supporting veterinarians and distribution partners with high-quality, bioequivalent treatment options across key therapeutic categories.

For additional information, please contact info@felixvet.com

About Felixvet

Founded in 2015 by Dr. Shumeet Banerji, Jon Symonds and Neeraj Agrawal, Felix develops and commercializes high-quality, bioequivalent pharmaceutical products for companion animals. The company is focused on expanding access to FDA-approved veterinary medicines through a growing portfolio of trusted treatment options for veterinarians and pet owners.

Media Contact

Paula Flavin
Project Marketing Manager, US Operations
D: 816-912-2000
E: info@felixvet.com

Felixvet Introduces Atipamezole Hydrochloride Injection for Reversal of Sedation and Analgesia in Dogs

Posted on by developer@wearewoodruff.com

Kansas City, Mo. — July 2, 2026 — Felixvet Inc. today announced the commercial availability of Atipamezole Hydrochloride Injection, a sterile injectable solution indicated for the reversal of the sedative and analgesic effects of dexmedetomidine hydrochloride and medetomidine hydrochloride in dogs. Atipamezole Hydrochloride Injection provides veterinarians with an FDA-approved option to support recovery following sedation procedures and expands Felixvet’s growing portfolio of companion animal pharmaceuticals.

Product Details

A 10 mL glass vial and the packaging box for Atipamezole Hydrochloride Injection with a small medical syringe and a folded product insert resting in front of the vial and packaging box.
Felixvet Atipamezole Hydrochloride Injection is available as a sterile injectable solution containing 5.0 mg/mL supplied in a 10 mL multidose vial.

“Veterinarians rely on predictable recovery protocols following sedation procedures, and Atipamezole Hydrochloride Injection provides an important FDA-approved option for reversing the sedative and analgesic effects of dexmedetomidine and medetomidine in dogs,” said Lauren Landolph, Vice President, Commercial Strategy & Distribution Channels, Felixvet. “We’re excited to expand our injectable portfolio and continue providing veterinary professionals with high-quality treatment options that support patient care throughout the procedural process.”

Atipamezole Hydrochloride Injection is indicated for the reversal of the sedative and analgesic effects of dexmedetomidine hydrochloride and medetomidine hydrochloride in dogs. The product is intended for intramuscular administration and is designed to support recovery following the use of these commonly utilized sedative agents.

Atipamezole Hydrochloride Injection is available as a 5.0 mg/mL sterile injectable solution supplied in a 10 mL multidose vial.

The product is approved for intramuscular use in dogs and is therapeutically equivalent to the pioneer product, providing the same safety and efficacy profile. As a reversal agent, Atipamezole Hydrochloride Injection serves as an important component of veterinary sedation protocols by helping veterinarians manage patient recovery following sedation procedures.

Felixvet continues to expand its portfolio of FDA-approved companion animal pharmaceuticals, supporting veterinarians and distribution partners with high-quality, bioequivalent treatment options across key therapeutic categories.

For additional information, please contact info@felixvet.com

About Felixvet

Founded in 2015 by Dr. Shumeet Banerji, Jon Symonds and Neeraj Agrawal, Felix develops and commercializes high-quality, bioequivalent pharmaceutical products for companion animals. The company is focused on expanding access to FDA-approved veterinary medicines through a growing portfolio of trusted treatment options for veterinarians and pet owners.

Media Contact

Paula Flavin
Project Marketing Manager, US Operations
D: 816-912-2000
E: info@felixvet.com

Felixvet Introduces Maropitant Citrate Chewable Tablets for the Prevention of Vomiting and Motion Sickness in Dogs

Posted on by developer@wearewoodruff.com

Kansas City, Mo. — June 30, 2026 — Felixvet Inc. today announced the commercial availability of Maropitant Citrate Chewable Tablets, an FDA-approved antiemetic indicated for the prevention of acute vomiting and the prevention of vomiting due to motion sickness in dogs. Approved by the U.S. Food and Drug Administration on January 12, 2026, under ANADA 200-833, the product expands Felixvet’s growing portfolio of companion animal pharmaceuticals and provides veterinarians with an important treatment option for one of the most common conditions seen in veterinary practice.

Product Details

Four different strengths of Maropitant Citrate chewable tablets for dogs, shown in both boxed packages and white bottles.
Felixvet Maropitant Citrate Chewable Tablets are indicated for the prevention of acute vomiting and the prevention of vomiting due to motion sickness in dogs.

“We’re excited to bring Maropitant Citrate Chewable Tablets to the veterinary market and expand access to a therapy veterinarians rely on every day,” said Lauren Landolph, Vice President, Commercial Strategy & Distribution Channels, Felixvet. “Vomiting and motion sickness are common challenges for dogs and their owners, and this approval provides veterinarians with an FDA-approved chewable formulation that offers convenience, dosing flexibility, and a trusted treatment option.”

Maropitant Citrate Chewable Tablets are indicated for the prevention of acute vomiting and the prevention of vomiting due to motion sickness in dogs.

The product is therapeutically equivalent to the pioneer drug and provides the same safety and efficacy profile. Maropitant Citrate Chewable Tablets are available in four strengths:

  • 16 mg 
  • 24 mg 
  • 60 mg 
  • 160 mg 

Each tablet is scored to support accurate dosing and is available in both bottle and blister pack presentations. 

“At Felixvet, we’re focused on bringing high-quality products to market that support the everyday needs of veterinarians and pet owners,” added Lauren Landolph. “The addition of Maropitant Citrate Chewable Tablets reflects our commitment to expanding access to important therapies across companion animal medicine.”

Felixvet continues to expand its portfolio of FDA-approved companion animal pharmaceuticals, supporting veterinarians and distribution partners with high-quality, bioequivalent treatment options across a broad range of therapeutic categories.

For additional information, please contact info@felixvet.com

About Felixvet

Founded in 2015 by Dr. Shumeet Banerji, Jon Symonds and Neeraj Agrawal, Felix develops and commercializes high-quality, bioequivalent pharmaceutical products for companion animals. The company is focused on expanding access to FDA-approved veterinary medicines through a growing portfolio of trusted treatment options for veterinarians and pet owners.

Media Contact

Paula Flavin
Project Marketing Manager, US Operations
D: 816-912-2000
E: info@felixvet.com

Felixvet Expands Xylitol-Free Meloxicam Portfolio for Dogs

Posted on by developer@wearewoodruff.com

Kansas City, Mo. — June 25, 2026 — Felixvet Inc. today announced expanded availability of its FDA-approved Meloxicam Oral Suspension, a prescription non-steroidal anti-inflammatory drug (NSAID) indicated for the control of pain and inflammation associated with osteoarthritis in dogs. Featuring a 100% xylitol-free formulation, Meloxicam Oral Suspension provides veterinarians and pet owners with a trusted treatment option designed specifically for canine patients.

Product Details 

Two Felix Meloxicam Oral Suspension box sizes (100 mL and 32 mL) for dogs, featuring blue and white branding.

Felixvet Meloxicam Oral Suspension is indicated for the control of pain and inflammation associated with osteoarthritis in dogs.

“Managing osteoarthritis is an important part of helping dogs maintain comfort, mobility, and quality of life,” said Lauren Landolph, Vice President, Commercial Strategy & Distribution Channels, Felixvet. “We’re proud to offer a 100% xylitol-free Meloxicam Oral Suspension that provides veterinarians and pet owners with a trusted FDA-approved treatment option while expanding availability across multiple package sizes to meet the needs of practices and patients.”

Osteoarthritis is one of the most common chronic conditions affecting dogs and can significantly impact mobility, activity levels, and overall comfort. Meloxicam Oral Suspension is indicated for the control of pain and inflammation associated with osteoarthritis and is formulated for convenient oral administration.

Meloxicam Oral Suspension contains 1.5 mg of meloxicam per milliliter and is available in the following bottle sizes:

  • 10 mL
  • 32 mL
  • 100 mL
  • 200 mL

The oral suspension should be shaken well before use and administered according to veterinary dosing instructions. The included dosing system helps support accurate measurement, particularly in small dogs.

“Veterinarians and pet owners value products that combine safety, convenience, and flexibility,” added Lauren Landolph. “The addition of multiple bottle sizes and a 100% xylitol-free formulation reflects our commitment to developing practical solutions that support the everyday management of chronic conditions such as osteoarthritis.”

Felixvet continues to expand its portfolio of FDA-approved companion animal pharmaceuticals, supporting veterinarians and pet owners with high-quality treatment options across a broad range of therapeutic categories. The original approval of Meloxicam Oral Suspension was announced in December 2025 and remains an important component of Felixvet’s growing pain management portfolio.

For additional information, please contact info@felixvet.com  

About Felixvet
Founded in 2015 by Dr. Shumeet Banerji, Jon Symonds and Neeraj Agrawal, Felix develops and commercializes high-quality, bioequivalent pharmaceutical products for companion animals. The company is focused on expanding access to FDA-approved veterinary medicines through a growing portfolio of trusted treatment options for veterinarians and pet owners. 

Media Contact:
Paula Flavin
Project/Marketing Manager
D: 1-816-912-2000
Email: info@felixvetus.com